There are 2934 resources available
Proffered Paper – Melanoma and other skin tumours - Invited Discussant LBA68_PR, LBA69 and 1311O
Presenter: Ulrich Keilholz
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Slides
Webcast
3562 - A phase 3 trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
Presenter: Karim Fizazi
Session: Proffered Paper – Translational research
Resources:
Abstract
Slides
Webcast
Proffered Paper – Translational research - Invited Discussant LBA15_PR and 1873O
Presenter: Sabine Linn
Session: Proffered Paper – Translational research
Resources:
Slides
Webcast
5639 - Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA)
Presenter: Geoffrey Oxnard
Session: Proffered Paper – Translational research
Resources:
Abstract
Slides
Webcast
811 - ENTRATA: Randomized, double-blind, phase 2 study of telaglenastat (tela; CB-839) + everolimus (E) vs. placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)
Presenter: Chung-Han Lee
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Proffered Paper 1 – Genitourinary tumours, non-prostate - Invited Discussant 901O and 902O
Presenter: Yohann Loriot
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Introduction
Presenter: Aurélien Marabelle
Session: Next challenges for cancer immunotherapy
Resources:
Slides
Webcast
Immunotherapy for locally advanced cancer
Presenter: Benjamin Besse
Session: Next challenges for cancer immunotherapy
Resources:
Slides
Webcast
Turning cold into hot tumours
Presenter: Aurélien Marabelle
Session: Next challenges for cancer immunotherapy
Resources:
Slides
Webcast
1900 - Initial Results From TROPHY-U-01: A Phase 2 Open-Label Study of Sacituzumab Govitecan in Patients (Pts) With Metastatic Urothelial Cancer (mUC) After Failure of Platinum-Based Regimens (PLT) or Immunotherapy
Presenter: Scott Tagawa
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast